Palisade Bio (PALI) News Today $0.67 0.00 (-0.33%) Closing price 04:00 PM EasternExtended Trading$0.66 0.00 (-0.39%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Maxim Group Sticks to Their Buy Rating for Palisade Bio (PALI)March 27, 2025 | markets.businessinsider.comPalisade Bio begins dosing subjects in last cohort of ulcerative colitis drug trialMarch 17, 2025 | finance.yahoo.comPalisade Bio commences dosing in first UC patient cohort in study of PALI-2108March 14, 2025 | markets.businessinsider.comPalisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108March 14, 2025 | globenewswire.comPalisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025March 12, 2025 | globenewswire.comPalisade Bio Participates in Virtual Investor “What This Means” SegmentMarch 4, 2025 | globenewswire.comPalisade Bio receives cash proceeds from Canada’s SR&ED tax incentive programFebruary 20, 2025 | markets.businessinsider.comPalisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)February 20, 2025 | globenewswire.comPalisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceFebruary 19, 2025 | globenewswire.comPalisade Bio presents preclinical data of PALI-2108February 10, 2025 | markets.businessinsider.comPalisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative ColitisFebruary 10, 2025 | globenewswire.comPalisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis CongressJanuary 30, 2025 | markets.businessinsider.comPalisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis CongressJanuary 29, 2025 | globenewswire.comPALI stock plunges to 52-week low, touches $1.34January 23, 2025 | msn.comPalisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment WebinarJanuary 23, 2025 | markets.businessinsider.comPalisade Bio begins MAD cohorts of Phase Ia/b ulcerative colitis therapy trialJanuary 17, 2025 | msn.comPalisade Bio completes all five SAD cohorts, advanced MAD cohorts for PALI-2108January 17, 2025 | markets.businessinsider.comPalisade's PALI-2108 Shows Tolerability Across 15mg To 450mg Doses In Ulcerative Colitis StudyJanuary 16, 2025 | markets.businessinsider.comPalisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative ColitisJanuary 16, 2025 | markets.businessinsider.comPalisade Bio reports positive data for UC drug trialJanuary 16, 2025 | msn.comPalisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)January 3, 2025 | globenewswire.comPalisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory BoardDecember 17, 2024 | globenewswire.comPalisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq RulesDecember 13, 2024 | globenewswire.comPalisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq RulesDecember 12, 2024 | globenewswire.com2026 Hyundai Palisade Reveals Boxy Stance And All-New InteriorDecember 7, 2024 | msn.comAnalysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Evolent Health (EVH) and Palisade Bio (PALI)December 5, 2024 | markets.businessinsider.comPalisade's Phase 1 Study Of PALI-2108 Shows No Treatment Related Adversities, Stock DownDecember 3, 2024 | markets.businessinsider.comPalisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated SubjectsDecember 3, 2024 | globenewswire.comPalisade Bio to present preclinical results for PALI-2108November 22, 2024 | markets.businessinsider.comBrookline Capital Initiates Coverage of Palisade Bio (PALI) with Buy RecommendationNovember 22, 2024 | msn.comPalisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)November 21, 2024 | globenewswire.comPalisade Bio initiated with a Buy at BrooklineNovember 20, 2024 | markets.businessinsider.comPalisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) SummitNovember 14, 2024 | markets.businessinsider.comPalisade Bio price target lowered to $8 from $22.50 at MaximNovember 14, 2024 | markets.businessinsider.comPalisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108November 12, 2024 | globenewswire.comPalisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)November 7, 2024 | markets.businessinsider.comPalisade Bio announces data from two ex vivo studies of PALI-2108November 2, 2024 | markets.businessinsider.comPalisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative ColitisOctober 31, 2024 | globenewswire.comBuy Rating for Palisade Bio Amid Novel UC Treatment Potential and Health Canada Trial ApprovalOctober 12, 2024 | markets.businessinsider.comPalisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)October 10, 2024 | globenewswire.comPalisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLCOctober 8, 2024 | finance.yahoo.comPalisade Bio (NASDAQ:PALI) Stock, Insider Trading ActivityOctober 5, 2024 | benzinga.comPalisade Bio (NASDAQ:PALI) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comEternal Strands - Official Setting TrailerSeptember 21, 2024 | msn.comPalisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision TherapiesSeptember 16, 2024 | markets.businessinsider.comBuy Rating on Palisade Bio Amidst UC Treatment Breakthrough and Strong Market PotentialSeptember 7, 2024 | markets.businessinsider.comPalisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient StratificationSeptember 5, 2024 | markets.businessinsider.comPalisade Bio, Inc.: Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 14, 2024 | finanznachrichten.deGalectin Flat on Quarterly FiguresAugust 13, 2024 | baystreet.caPalisade Bio Edges up on Q2 ResultsAugust 13, 2024 | baystreet.ca Remove Ads Get Palisade Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter. Email Address PALI Media Mentions By Week PALI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PALI News Sentiment▼-0.500.57▲Average Medical News Sentiment PALI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PALI Articles This Week▼12▲PALI Articles Average Week Remove Ads Get Palisade Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ONCO News CYCN News AYTU News UPC News BTAI News NKGN News HOTH News BFRI News OMGA News ALZN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PALI) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PALI Stock Free PALI Stock Alerts